Sign in
4

Changes in Ownership

Enliven Therapeutics, Inc. Filed Acc 0001415889-25-012030

PRESIDENT AND CEO sold 7,500 shares at an average $20.06 ($150,415)

  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Kintz Samuel · PRESIDENT AND CEO

Table I: Non-derivative

2 lines
Date Transaction Shares Price Value Owned after D/I
2025-05-01 Sale : show line 1 in the form 10b5-1 −5,330 $20.08 $107,007 980,062 I
2025-05-02 Sale : show line 2 in the form 10b5-1 −2,170 $20.00 $43,409 977,892 I
Open-market sales · 7,500 sh · avg $20.06 · $150,415
Loading xslF345X05/form4-05052025_100514.xml…